Przejdź do zawartości
Merck
Wszystkie zdjęcia(2)

Kluczowe dokumenty

HMHEMAG-34K

Millipore

MILLIPLEX® Human Metabolic Hormone Magnetic Bead Panel - Metabolism Multiplex Assay

The Human Metabolic Hormone Panel, using the Luminex xMAP technology, enables the simultaneous analysis of 13 protein biomarkers in human serum, plasma and cell/tissue culture samples.

Synonim(y):

Millipore zestaw multipleksowy metabolizmu ludzkiego, luminex test multipleksowy ludzkiego hormonu metabolicznego, panel testów immunologicznych ludzkich hormonów metabolicznych

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12161503
eCl@ss:
32161000

To order a Milliplex® kit, please search for your analyte of interest.

reaktywność gatunkowa

human

producent / nazwa handlowa

Milliplex®

assay range

accuracy: 101%
(Glucagon)

accuracy: 102%
(Leptin)

accuracy: 103%
(GIP)

accuracy: 103%
(GLP-1 (Total))

accuracy: 105%
(Ghrelin (Active))

accuracy: 106%
(MCP-1)

accuracy: 97%
(TNFα)

accuracy: 99%
(C-Peptide)

sensitivity: 0.5 pg/mL
(MinDC+2SD; TNF?)

sensitivity: 1.1 pg/mL
(MinDC+2SD; GIP)

sensitivity: 13 pg/mL
(MinDC+2SD; IL-6)

sensitivity: 14 pg/mL
(MinDC+2SD; Ghrelin (Active))

sensitivity: 14 pg/mL
(MinDC+2SD; MCP-1)

sensitivity: 146 pg/mL
(MinDC+2SD; PYY)

sensitivity: 15 pg/mL
(MinDC+2SD; Amylin (Total))

sensitivity: 16 pg/mL
(MinDC+2SD; C-Peptide)

sensitivity: 16 pg/mL
(MinDC+2SD; Glucagon)

sensitivity: 160 pg/mL
(MinDC+2SD; Insulin)

sensitivity: 2.4 pg/mL
(MinDC+2SD; GLP-1 (Active))

sensitivity: 2.9 pg/mL
(MinDC+2SD; PP)

sensitivity: 28 pg/mL
(MinDC+2SD; Amylin (Active))

sensitivity: 64 pg/mL
(MinDC+2SD; Leptin)

sensitivity: 7.3 pg/mL
(MinDC+2SD; GLP-1 (Total))

standard curve range: 0.69-500 pg/mL
(TNFα)

standard curve range: 1.4-1,000 pg/mL
(GIP)

standard curve range: 13.7-10,000 pg/mL
(Amylin (Active))

standard curve range: 13.7-10,000 pg/mL
(Amylin (Total))

standard curve range: 13.7-10,000 pg/mL
(Ghrelin (Active))

standard curve range: 13.7-10,000 pg/mL
(Glucagon)

standard curve range: 13.7-10,000 pg/mL
(IL-6)

standard curve range: 13.7-10,000 pg/mL
(MCP-1)

standard curve range: 13.7-10,000 pg/mL
(PYY)

standard curve range: 137-100,000 pg/mL
(Insulin)

standard curve range: 137-100,000 pg/mL
(Leptin)

standard curve range: 2.7-2,000 pg/mL
(GLP-1 (Active))

standard curve range: 2.7-2,000 pg/mL
(GLP-1 (Total))

standard curve range: 2.7-2,000 pg/mL
(PP)

standard curve range: 27.4-20,000 pg/mL
(C-Peptide)

inter-assay cv: <15%
intra-assay cv: <10%
(C-Peptide)

inter-assay cv: <15%
intra-assay cv: <10%
(GIP)

inter-assay cv: <15%
intra-assay cv: <10%
(GLP-1 (Active))

inter-assay cv: <15%
intra-assay cv: <10%
(GLP-1 (Total))

inter-assay cv: <15%
intra-assay cv: <10%
(Ghrelin (Active))

inter-assay cv: <15%
intra-assay cv: <10%
(Glucagon)

inter-assay cv: <15%
intra-assay cv: <10%
(IL-6)

inter-assay cv: <15%
intra-assay cv: <10%
(Insulin)

inter-assay cv: <15%
intra-assay cv: <10%
(Leptin)

inter-assay cv: <15%
intra-assay cv: <10%
(MCP-1)

inter-assay cv: <15%
intra-assay cv: <10%
(PP)

inter-assay cv: <15%
intra-assay cv: <10%
(PYY)

inter-assay cv: <15%
intra-assay cv: <10%
(TNFα)

inter-assay cv: <20%
intra-assay cv: <10%
(Amylin (Active))

inter-assay cv: <20%
intra-assay cv: <10%
(Amylin (Total))

metody

multiplexing: suitable

metoda wykrywania

fluorometric (Luminex xMAP)

Warunki transportu

wet ice

Opis ogólny

Metabolic syndrome is a cluster of conditions, including increased blood pressure, elevated insulin levels, excess body fat around the waist, and abnormal cholesterol levels. Key features of metabolic syndrome include insulin resistance, glucose intolerance, hypertension, dyslipidemia, and central obesity—all of which are risk factors for atherosclerosis, coronary heart disease, type 2 diabetes, kidney disease, and even premature death. Adults with metabolic syndrome present a low-grade inflammation, whose link with obesity may be a production of pro- and anti-inflammatory factors. Consequently, research done in this area covers multi-faceted fields of cytokines, acute phase proteins, diabetes, and obesity related hormones, as well as other cardiovascular disease biomarkers.

The MILLIPLEX® Human Metabolic Hormone Panel is a 15 analyte, 13-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and cell/tissue culture samples: Amylin (Active) or Amylin (Total), C-Peptide, Ghrelin (Active), GIP, GLP-1 (Active) or GLP-1 (Total), Glucagon, IL-6, Insulin, Leptin, MCP-1, PP, PYY, TNFα. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Metabolism

Zastosowanie

  • Analytes: Amylin (Active), Amylin (Total), C-Peptide, Ghrelin (Active), GIP (Total), GLP-1 (Active), GLP-1 (Total), Glucagon, IL-6, Insulin, Leptin, MCP-1 (CCL2), Pancreatic Polypeptide (PP), PYY (Total), TNF-α
  • NOTE: The following analytes cannot be assayed simultaneously: Amylin (Active) & Amylin (Total); GLP-1 (Active) & GLP-1 (Total).
  • Recommended Sample Type: Human serum, plasma, and cell/tissue culture supernatants or lysates
  • Recommended Sample Dilution: 25 μL per well of undiluted serum or plasma; cell/tissue culture samples may be used undiluted or diluted with an appropriate control medium NOTE: The following analytes require the addition of protease inhibitors to serum or plasma samples (see sample collection and storage section in the protocol for details): GLP-1 (DPPIV inhibitor); Amylin (protease inhibitor cocktail); Glucagon (Aprotinin); Ghrelin (Active) (serine protease inhibitor).
  • Assay Run Time: Overnight (16-18 hours) at 2-8°C
  • Research Category: Metabolism
  • Research Subcategory: Metabolic Disorders

Cechy i korzyści

Design your multiplex kit by choosing available analytes within this panel.

Powiązanie

Replaces: HMHMAG-34K

Inne uwagi

Please contact Technical Service for linearity of dilution.
Please note: Amylin (Active) and Amylin (Total) cannot be plexed together. GLP-1 (Active) and GLP-1 (Total) cannot be plexed together.

Informacje prawne

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Ta strona może zawierać tekst przetłumaczony maszynowo.

Piktogramy

Skull and crossbonesEnvironment

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

Klasyfikacja zagrożeń

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Sens. 1

Kod klasy składowania

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Marta Klementova et al.
Nutrients, 11(1) (2019-01-16)
Gastrointestinal hormones are involved in regulation of glucose metabolism and satiety. We tested the acute effect of meal composition on these hormones in three population groups. A randomized crossover design was used to examine the effects of two energy- and
Matthieu St-Jean et al.
PloS one, 12(5), e0177110-e0177110 (2017-05-12)
Hepatocyte nuclear factor 1 alpha (HNF1α) defects cause Mature Onset Diabetes of the Young type 3 (MODY3), characterized by defects in beta-cell insulin secretion. However, HNF1α is involved in many other metabolic pathways with relevance for monogenic or polygenic type
Lijuan Sun et al.
The British journal of nutrition, 116(7), 1216-1221 (2016-09-10)
Apart from the well-known action of insulin, the mechanism by which soya and cows' milk improve postprandial glycaemia control was examined. In total, twelve healthy, young, Chinese men were studied on three separate occasions, in random order with isovolumetric (322
Patrik Hansson et al.
The Journal of nutrition, 149(3), 422-431 (2019-02-14)
Postprandial lipemia is a risk factor for cardiovascular disease. Dairy products differ in nutrient content and food matrix, and little is known about how different dairy products affect postprandial triglyceride (TG) concentrations. We investigated the effect of meals with similar
Gabriella A Heruc et al.
American journal of physiology. Endocrinology and metabolism, 315(4), E565-E573 (2018-07-04)
Postprandial glucose is reduced in malnourished patients with anorexia nervosa (AN), but the mechanisms and duration for this remain unclear. We examined blood glucose, gastric emptying, and glucoregulatory hormone changes in malnourished patients with AN and during 2 wk of

Powiązane treści

Wielokrotne testy immunologiczne oszczędzają czas i ilość próbek w badaniach nad zespołem metabolicznym, zapewniając kompleksowy wgląd w powiązane schorzenia.

Questions

1–2 of 2 Questions  
  1. How much protease inhibitor should be added when using only the plasma instead of the entire blood sample?

    1 answer
    1. For most protease inhibitors, such as leupeptin and aprotinin, doubling the concentration typically does not negatively impact the assay. However, with specific inhibitors like the DPPIV inhibitor referenced, higher concentrations can interfere with the assay, which is why additional instructions are provided. Other DPPIV inhibitors, such as Diprotin A, do not interfere at any concentration but are not as effective.

      Helpful?

  2. Could you please provide information on the epitopes targeted by the antibodies HMHE-1034-2 and HMHE-1034-1, which are used in the MILLIPLEX MAP Human Metabolic Hormone Magnetic Bead Panel - Metabolism Multiplex Assay? Specifically, I would like to know if the anti-GLP-1 antibody would be able to bind to a commercial drug such as semaglutide.

    1 answer
    1. This antidiabetic medication for the treatment of type 2 diabetes and as anti-obesity medication for long-term weight management is known as Semaglutide. It is sold under the brand names Ozempic, Wegovy, and Rybelsus. Semaglutide was developed by Novo Nordisk in 2012. It is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control.

      Helpful?

Reviews

No rating value

Active Filters

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej